Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Daniel W Sherbenou

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Email

    Collapse Biography 
    Collapse awards and honors
    2014 - 2015Young Investigator Award - Grand Multiple Myeloma Translational Initiative, University of California, San Francisco
    1998 - 1999Undergraduate Honors Thesis: Two-hybrid screen for Sur-2 interactions in the C. elegans Ras pathway, University of Colorado at Boulder
    2016 - 2016Paul O'Hara II Seed Grant, University of Colorado Cancer Center
    2016 - 20182016 Young Investigator Award, NCCN Foundation

    Collapse Overview 
    Collapse overview
    As an undergraduate at the University of Colorado, I started by scientific career focused on basic science research of cancer. In the laboratory of Dr. Min Han, I studied the Ras cell signaling pathway using the C. elegans model organism. In the MD/PhD program at Oregon Heath & Science University, I focused on translational leukemia research. Under the mentorship of Drs. Brian Druker and Michael Deininger, I focused on chronic myeloid leukemia. My thesis evaluated mechanisms of kinase inhibitor resistance in patients treated with imatinib (Gleevec). In oncology fellowship at University of California at San Francisco, I focused on the study of antibody-based therapeutics under the mentorship of Dr. Bin Liu. Antibody-drug conjugates (ADCs) are another rapidly growing approach to cancer treatment. With Dr. Liu, I conducting preclinical analyses of a novel ADC for multiple myeloma, with hope this this to soon lead to transition to the clinic. Now a faculty member at UC Denver in the Hematology division, I will oversee a translational research laboratory focused on novel therapy development and optimization for multiple myeloma and will care for patients with myeloma and related plasma cell disorders of Colorado and adjoining areas.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Dec 01; 126(12):4640-4653. PMID: 27841764.
      View in: PubMed
    2. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91. PMID: 25294123.
      View in: PubMed
    3. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 2010 Oct 28; 116(17):3278-85. PMID: 20519627.
      View in: PubMed
    4. Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008 Jun; 22(6):1184-90. PMID: 18354488.
      View in: PubMed
    5. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest. 2007 Aug; 117(8):2067-74. PMID: 17671641.
      View in: PubMed
    6. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 2007 Mar; 21(3):489-93. PMID: 17252009.
      View in: PubMed
    7. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006 Dec 01; 66(23):11156-65. PMID: 17145859.
      View in: PubMed
    8. O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6987-93. PMID: 16203792.
      View in: PubMed
    Sherbenou's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)